Name: UMIN ID:
Unique ID issued by UMIN | UMIN000021552 |
---|---|
Receipt number | R000024664 |
Scientific Title | Open, randomized, active-controlled insulin resistance outcome trial of safety and efficacy with empagliflozin in type 2 diabetic patients |
Date of disclosure of the study information | 2016/03/30 |
Last modified on | 2020/09/23 16:46:34 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2016/03/21 10:29:53 | ||
2 | Update | 2016/04/03 15:24:26 | Name of primary person or sponsor Organization Category of Funding Organization |
|
3 | Update | 2016/04/03 15:45:06 | Acronym Acronym |
|
4 | Update | 2017/03/22 23:32:18 | Last follow-up date |
|
5 | Update | 2017/07/03 22:47:02 | Recruitment status Last follow-up date |
|
6 | Update | 2018/03/22 12:55:58 | Last follow-up date |
|
7 | Update | 2018/09/21 11:05:36 | Last follow-up date |
|
8 | Update | 2018/10/16 20:36:48 | Research ethics review |
|
9 | Update | 2019/03/23 18:10:44 | Date of IRB |
|
10 | Update | 2019/03/23 18:13:05 | Number of participants that the trial has enrolled |
|
11 | Update | 2019/09/22 09:58:55 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Email2 Email3 Organization Organization Address Address Tel |
|
12 | Update | 2020/03/23 10:05:29 | Last follow-up date |
|
13 | Update | 2020/03/24 13:26:09 | Email1 Email3 |
|
14 | Update | 2020/09/23 16:44:38 | URL releasing protocol URL related to results and publications Number of participants that the trial has enrolled Results Results Results date posted Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures |
|
15 | Update | 2020/09/23 16:45:51 | Recruitment status |
|
16 | Update | 2020/09/23 16:46:34 | Publication of results Participant flow |